» Articles » PMID: 22132747

The Relationship Between the Bladder Volume and Optimal Treatment Planning in Definitive Radiotherapy for Localized Prostate Cancer

Overview
Journal Acta Oncol
Specialty Oncology
Date 2011 Dec 3
PMID 22132747
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is no current consensus regarding the optimal bladder volumes in definitive radiotherapy for localized prostate cancer. The aim of this study was to clarify the relationship between the bladder volume and optimal treatment planning in radiotherapy for localized prostate cancer.

Material And Methods: Two hundred and forty-three patients underwent definitive radiotherapy with helical tomotherapy for intermediate- and high-risk localized prostate cancer. The prescribed dose defined as 95% of the planning target volume (PTV) receiving ≧ 100% of the prescription dose was 76 Gy in 38 fractions. The clinical target volume (CTV) was defined as the prostate with a 5-mm margin and 2 cm of the proximal seminal vesicle. The PTV was defined as the CTV with a 5-mm margin. Treatment plans were optimized to satisfy the dose constraints defined by in-house protocols for PTV and organs at risk (rectum wall, bladder wall, sigmoid colon and small intestine). If all dose constraints were satisfied, the plan was defined as an optimal plan (OP).

Results: An OP was achieved with 203 patients (84%). Mean bladder volume (± 1 SD) was 266 ml (± 130 ml) among those with an OP and 214 ml (±130 ml) among those without an OP (p = 0.02). Logistic regression analysis also showed that bladder volumes below 150 ml decreased the possibility of achieving an OP. However, the percentage of patients with an OP showed a plateau effect at bladder volumes above 150 ml.

Conclusions: Bladder volume is a significant factor affecting OP rates. However, our results suggest that bladder volumes exceeding 150 ml may not help meet planning dose constraints.

Citing Articles

A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability.

Jin W, Montoya C, Rich B, Seldon Taswell C, Noy M, Kwon D JMIR Cancer. 2024; 10:e51061.

PMID: 39255484 PMC: 11422727. DOI: 10.2196/51061.


Optimal Bladder Volume for Hypofractionated Proton Therapy in Each Localized Prostate Cancer Risk Group.

Narita Y, Kato T, Ishikawa Y, Takemasa K, Yamaguchi H, Murakami M Cureus. 2023; 15(11):e48723.

PMID: 38094565 PMC: 10716574. DOI: 10.7759/cureus.48723.


Optimal Bladder Condition in Volumetric Modulated Arc Therapy for Prostate Cancer: The Role of Superior-Inferior Lengths of the Bladder and Dose Constraints.

Ishikawa Y, Narita Y, Ito K, Teramura S, Yamada T Cureus. 2023; 15(10):e47148.

PMID: 37849824 PMC: 10578987. DOI: 10.7759/cureus.47148.


Assessment of an ultrasound bladder scanner in prostate radiotherapy: A validation study and analysis of bladder filling variability.

Smith L, Gittins J, Ramnarine K, Chung E Ultrasound. 2022; 30(1):36-43.

PMID: 35173777 PMC: 8841937. DOI: 10.1177/1742271X21995217.


Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer.

Grun A, Kawgan-Kagan M, Kaul D, Badakhshi H, Stromberger C, Budach V Strahlenther Onkol. 2018; 195(6):517-525.

PMID: 30443682 DOI: 10.1007/s00066-018-1398-8.